The U.S. market for diagnostic radiopharmaceuticals, which was $1.69 billion in 2005, is expected to double to $3.52 billion by 2012, according to a recent study by market research firm Bio-Tech Systems.
The Las Vegas-based company said that radiopharmaceutical sales grew 8.1% in 2005, diminishing somewhat from the previous year, but should resume growth in the range of 11% to 12% per year. This forecast is based on the introduction of new products for cardiology and oncology, and continued growth of PET imaging and sales of FDG, Bio-Tech Systems said.
Much of the market growth in the field will be driven by nuclear cardiology. The report predicts high utilization of nuclear perfusion studies, coupled with advanced pharmacologic stress agents and the introduction of new products for imaging myocardial infarction and congestive heart failure. Nuclear cardiology sales were $1.21 billion in 2005 and will increase to $2.11 billion by 2012, the firm said.
FDG sales, which were $259 million in 2005, should increase to $933 million by 2012, Bio-Tech Systems forecast. The full report is available via the company's Web site.
By AuntMinnie.com staff writers
October 10, 2006
Related Reading
PET market continues double-digit growth, June 9, 2006
New promise for therapeutic radiopharmaceuticals, June 2, 2006
Therapeutic radiopharmaceutical market poised for takeoff, February 20, 2006
Can SPECT/CT revitalize nuclear medicine? July 7, 2005
Report projects rapid PET procedure growth, July 6, 2005
Copyright © 2006 AuntMinnie.com
